Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific ...
A biomedical researcher combining advanced mouse models with human-based and computational approaches explains why we can’t ...
News-Medical.Net on MSN
New molecule offers a promising avenue to treat triple-negative breast cancer
A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable ...
A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable cases of triple-negative breast cancer — a form of cancer that is ...
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
Lunai Bioworks (LNAI) has announced a major scientific breakthrough: its next-generation immune cell therapy led to complete regression of both ...
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P ...
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors NRM-823 is a T cell ...
HCW Biologics debuted the results from its preclinical study of HCW11-018b, the Company’s lead T-cell engager product candidate, that highlights the uniqueness and advantages of its second-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback